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Abstract
Early detection and management of elevated blood pressure is crucial in reducing the burden of cardio-
vascular disease (CVD). The importance of an absolute risk assessment and patient risk stratification 
has been highlighted in the European hypertension guidelines since 2003. Amongst numerous risk fac-
tors influencing patient prognosis, elevated heart rate (HR) has been indicated as important predictor 
of future risk of hypertension, coronary heart disease, sudden cardiac death, heart failure, CVD, stroke, 
total cancer and mortality. Given that resting HR can be easily determined in clinical practice and 
modified by lifestyle changes as well as beta-blocker therapy, it seems reasonable that lowering resting 
HR should be a potential target to reduce disease burden and premature mortality. However, there is a 
lack of outcome studies of HR lowering in tachycardia-related hypertension. This review outlines the 
underlying mechanisms of early course hypertension pathophysiology with the critical role of the sym-
pathetic nervous system activation, the prognostic significance of fast HR and the mechanistic rationale 
for the use of non-pharmacological approaches and/or highly long-acting cardioselective beta-blockers 
with some consideration given to betaxolol properties. (Cardiol J XXXX; XX, X: xx–xx)
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Introduction
Hypertension remains the leading preventable 
cause of premature deaths worldwide. Despite ad-
vances in hypertension prevention, diagnosis and 
treatment, elevated blood pressure (BP) affects 
at least one third of the adult global population ac-
cording to national surveys [1, 2]. Using the recent 
American College of Cardiology and the American 
Heart Association guidelines for hypertension 
definition, the overall burden of the disease is 
even higher [3], likely to rise further due to the 
increasing prevalence of obesity worldwide. Nota-
bly, the incidence of cardiovascular (CV) disease 
(CVD) (i.e. myocardial infarction [MI], stroke, heart 
failure [HF], peripheral artery disease, kidney 
disease) directly increases from the threshold of 
115/75 mmHg in all age groups, in both men and 
women [4].
Essential hypertension is the most common 
form of hypertension with no identifiable cause 
affecting nearly 95% of hypertensive patients. 
The pathogenesis of primary hypertension is 
multifactorial and numerous interrelated factors 
including salt intake, obesity, insulin resistance, 
genetics, endothelial dysfunction, low birth weight, 
intrauterine malnutrition and vascular anomalies 
contribute to raised BP and its relative impact may 
vary between individuals. 
Further emerging risk factor gaining an impor-
tant recognition is elevated resting heart rate (HR). 
Tachycardia can reflect a normal body response 
to various stimuli such as stress, fever, alcohol, 
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conditions (e.g. anemia, thyroid problems, infec-
tion, other). While in clinical practice fast HR can 
be unnoticed or viewed as a sign of ‘nervousness’, 
there is evidence to indicate that the presence of 
tachycardia and increased cardiac output (CO) are 
hemodynamic features of early phase of arterial hy-
pertension [5] and important contributors to estab-
lished hypertension and CVD [6]. Most studies on 
hypertension have reported that a HR higher than 
80–85 bpm confers increased CV and mortality risk 
[6]. Although the presence of HR of > 80 bpm has 
been added to patient risk evaluation as per recent 
European Society of Cardiology and the European 
Society of Hypertension guidelines [7], the use 
of beta-blockers in uncomplicated hypertension 
is still under debate and the therapeutic approach 
to patients presenting with hypertension-related 
tachycardia remains empirical. CV outcomes of 
hypertensive patients treated or non-treated with 
beta-blockers are inconclusive. Optimal HR levels 
for hypertensive patients need to be determined. 
Hemodynamic pattern  
of essential hypertension
Hemodynamic characteristics of the initial 
phase of primary essential hypertension are not 
unequivocal, either induced by raised CO or in-
creased peripheral resistance [8]. It has been 
documented that in not less than 30% of children 
and younger population, fast HR and CO but normal 
total peripheral resistance precedes the develop-
ment of high BP. The Tecumseh Blood Pressure 
Study found that 37% of all patients with untreated 
borderline and/or mild hypertension demonstrated 
hyperkinetic state with elevated HR, CO, forearm 
blood flow and plasma noradrenaline (NA) levels 
resulting in high sympathetic tone and decreased 
parasympathetic tone [9]. The hyperkinetic state 
caused by excessive autonomic drive is likely to 
be induced by augmented sympathetic activity to 
the heart and kidney. This selectively elevated NA 
release from renal and cardiac sympathetic nerves 
in essential hypertension has been predominantly 
found in males under the age of 40 [10]. 
High sympathetic activity is likely to be the 
underlying mechanism through which HR is as-
sociated with high insulin levels, insulin resist-
ance, dyslipidemia, high hematocrit and excess 
body weight. Indeed, patients with hypertension 
commonly display other metabolic abnormalities 
including elevated glucose, insulin and lipid levels 
which importantly contribute to the HR increase 
[11, 12]. Weight gain and a lack of physical activity 
are further independent factors associated with 
resting tachycardia. Accelerated HR is associated 
with the magnitude of BP levels [13–16]. Own 
clinical experience suggests that pre-diabetes 
and obstructive sleep apnea are not uncommon 
conditions associated with tachycardia-related 
hypertension (as summarized in Fig. 1).
With aging and disease progression, CO gen-
erally normalized in uncomplicated hypertension, 
however a shift toward increased vascular resist-
ance potentiates sympathetic activation which is 
a hallmark of established hypertension. In un-
controlled hypertension, persistent sympathetic 
activation promotes vascular remodeling, organ 
damage and adverse CV complications (Fig. 1) [17]. 
Fast HR in turn not only increases BP and 
leads to sustained hypertension but also exerts 
hemodynamically mediated cardiac abnormalities 
leading to reduced coronary flow reserve and vas-
cular compliance, promoting atherosclerosis, arte-
rial remodeling and plaque instability, endothelium 
dysfunction and microalbuminuria, importantly 
contributing to myocardial ischemia, coronary ar-
tery disease and HF (Fig. 1). Subsequently, the risk 
of ischemic heart disease, MI, cardiac arrhythmia 
and sudden cardiac death have been closely linked 
to the increased magnitude of HR [18].
Sympathetic activation  
in essential hypertension
Neurogenic activation underlies no less than 
50% of all cases of high BP [19]. With the use of 
two state of the art methods such as the isotope 
dilution technique (to estimate the release of NA 
from the sympathetic nerves innervating internal 
organ) and the technique of microneurography (to 
directly assess postganglionic muscle sympathetic 
nerve activity [MSNA]), it has been documented 
that hypertension is commonly neurogenic, with 
the rise in BP being initiated and sustained as a 
result of potentiated sympathetic activation in the 
kidney and the heart — the two organs critically 
involved in neural control of circulation and BP [19, 
20]. Increased activity of MSNA has been found in 
low risk subjects with high-normal BP [21] sug-
gesting that neurogenic excitation may precede 
overt arterial hypertension [22]. A long-term study 
documented that in subjects with prehypertension 
MSNA tracking corresponds with BP changes over 
time suggesting that tonic activation is likely to 
influence a time-related increase in resting BP 
and development of sustained hypertension in 
prehypertension [23]. In patients with resistant 
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hypertension, sympathetic activation is further 
potentiated, reaching the MSNA levels directly 
corresponding to HR levels [24, 25]. Furthermore, 
sympathetic nervous system activation has been 
documented as the underlying critical cause of 
hypertension-mediated organ damage [26–28] and 
independent predictor of mortality and poor CV 
outcomes [29]. 
Link between tachycardia  
and sympathetic activation
Tachycardia and resultant hyperkinetic circula-
tion if sustained over time, leads to an autonomic 
imbalance and reduced heart rate variability [30]. 
Microneurographic studies found that sympathetic 
activity and HR exerts an interactive effect on BP 
levels [31]. In normotensive subjects (males only, 
not females) with faster HR, higher levels of MSNA 
has been linked to higher systolic BP and pulse 
pressure whereas no similar relationship could 
be found in subjects with lower HR [31]. On the 
contrary, the relationship between resting HR and 
MSNA in hypertension is more complex and not 
completely understood. It has been documented 
that HR may be not a reliable indicator of the over-
all sympathetic activity as no association has been 
found between supine resting office HR and MSNA 
in essential hypertension [32]. Notably, ambulatory 
HR was found to be a superior risk marker to clinic 
or HR derived from an electrocardiogram (ECG) 
[33]. Indeed, when 24-h ambulatory BP measure-
ments were applied, MSNA levels have been di-
rectly related to ambulatory daytime and night-time 
HR in a large sample of patients with untreated 
essential hypertension that were independent of 
age, body mass index (BMI) and gender [34]. This 
observation is likely to explain recent findings 
demonstrating the predictive role of masked (and/
or sustained) tachycardia but not office tachycardia 
in future CV events and mortality [35]. 
Heart rate as risk factor  
for cardiovascular disease
Over the past decade elevated HR has gained 
recognition as an important risk factor for the 
development of CVD. Numerous epidemiological 
studies have reported an independent associa-
tion between tachycardia and CV morbidity and 
mortality in the general population [18], subjects 
with prehypertension, patients with hypertension 
[12], CVD [36], HF [37], total cancer and all-cause 
mortality [38]. The prognostic value of both home 
[39] and ambulatory HR [40] has been indicated in 
the Ohasama Study which included individuals from 
the Japanese general population with no previous 
history of CVD including arrhythmia. An increase 
of 5 bpm in the morning home HR measurement 




















Figure 1. Factors contributing to elevated heart rate and pathophysiological consequences of tachycardia.
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mortality which remained statistically significant 
after adjustment for home BP values. Moreo-
ver, even subjects with HR ≥ 70 bpm and home-
measured systolic BP within the normal range 
(< 135 mmHg) had a higher risk of CV mortality 
compared to those with normal systolic BP and 
HR values [39]. Further analysis of the Ohasama 
study revealed that both daytime and nighttime 
HR predicted all-cause mortality over a 12-year 
period, however only nighttime HR remains the 
most important and independent predictor of non-
CV mortality [40]. 
Further proof for the predictive role of HR on 
CV morbidity primarily in hypertensive men comes 
from the Framingham study suggesting that HR 
and BP may act synergistically in the development 
of CV complications [13]. Supportive evidence for 
fast HR-related outcomes was also documented 
in the Valsartan Antihypertensive Long-Term Use 
Evaluation (VALUE) trial which included patients 
with high-risk hypertension followed over a 5-year 
period [41]. It was found that patients in the highest 
HR quintile had a greater risk for cardiac events 
when compared to patients in the lowest HR quin-
tile [41]. Notably, the adverse impact of elevated 
HR on patient prognosis was unrelated to BP con-
trol indicating that even patients with reasonably 
well-controlled hypertension but the presence of 
tachycardia are at high risk for CV events. 
Tachycardia is also a strong predictor of exces-
sive coronary morbidity and CV mortality [42]. A 
large study of French population found that acceler-
ated resting HR was an independent predictor of 
non-CV mortality in both genders, and CV mortal-
ity in men, independent of age and the presence 
of hypertension [14]. In this study the HR-related 
increase in CVD mortality was due to a rise in 
coronary death but not cerebrovascular mortality. 
Another long-term study found that individuals 
with coexisting hypertension and elevated HR had 
increased risk of both stroke and coronary heart 
disease [43]. This is likely to occur as a result of 
plaque disruption due to hemodynamic forces (i.e. 
hypertension-induced left ventricular hypertrophy 
and elevated HR) which is a crucial pathophysi-
ological mechanism underlying acute coronary syn-
drome and the progression of atherosclerosis [44].
There is evidence to indicate that not only 
masked hypertension is associated with an in-
creased risk for CVD, but also masked tachycardia 
significantly increased rates of CV events and 
all-cause mortality [45]. Masked tachycardia has 
been defined as HR levels values ≤ 85 bpm in 
the clinic, but an elevated HR out of the clinic 
(ambulatory mean nighttime > 76 bpm) [45]. 
Masked tachycardia may occur in as many as 10% 
of the hypertensive population, and is important 
because it is not diagnosed by routine medical 
examinations, but carries an adverse prognosis, 
both in terms of increased target organ damage 
and CV events. Possible characteristics of indi-
viduals with masked tachycardia are relatively 
young patients, smokers, sufferers of diabetes or 
other metabolic disorders, and those who have 
elevated HR in outpatient settings [45, 46]. The 
negative association between masked tachycardia 
and an increased risk for major CV events and 
all-cause mortality was documented in a study of 
7602 patients with newly diagnosed hypertension 
who were followed over a duration of 5 years [45]. 
Patients presenting with sustained tachycardia (in-
creased both HR in the office and ambulatory night-
time measurements) had an increased risk of major 
CV events, but not mortality. After adjustment for 
additional risk factors including age, gender, BMI, 
lipid profile and creatinine levels, but not smoking 
and diabetes, both masked and sustained tachycar-
dia were associated with greater risk of CV events 
[45]. While the type of beta-blockers used has not 
been indicated in this study, it is notable that the 
prognostic significance of tachycardia in predicting 
future major adverse CV events is independent of 
beta-blocker use [45].
The prognostic significance of elevated resting 
HR has been also found in patients with resistant 
hypertension [33] in whom not only fast (> 75 
bpm or > 70 bpm for nighttime HR), but also slow 
HR (< 60 bpm or < 55 bpm for nighttime HR) 
predicted CV death. Importantly, approximately 
80% of patients from this cohort were treated with 
beta-blockers which had an impact on HR-related 
prognosis. Fast HR was a significant risk marker 
in patients using beta blockers, whereas slow HR 
was a predictor in those not using beta-blockers 
suggesting an overall U-shaped phenomenon be-
tween the levels of HR and outcomes in patients 
with resistant hypertension [33]. In view of these 
findings, it appears that despite achieved BP con-
trol, hypertensive patients can remain at high risk 
for CV and/or non-CV complications. 
Beta-blockers in hypertension 
Despite the mechanistic rationale for the use 
of beta-blockers in the treatment of hypertension-
related tachycardia, their therapeutic usefulness 
has been questioned based on the outcomes from 
meta-analyses of clinical trials. It has been sug-
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gested that therapy with beta-blockers may not 
preclude future CV events and mortality in hyper-
tension. Meta-analysis of a large cohort of patients 
(n = 94,492) with hypertension found that therapy 
with beta-blockers led to an increased risk for new-
onset diabetes mellitus, occurrence of stroke with 
no benefit for the hard end-point of death or MI 
compared to other antihypertensive agents [47]. 
Further analysis of randomized controlled trials 
evaluating beta-blockers use in patients with hy-
pertension (n = 34,096) when compared to patients 
(n = 30,139) taking other antihypertensive agents 
or patients receiving placebo (n = 3987) indicated 
that a lower HR (as attained in the beta-blocker 
group at study end) was associated with greater 
risk for end points of all-cause mortality, CV mor-
tality, MI, stroke and HF [48]. Notably, nearly 75% 
of all clinical studies used as reference, atenolol 
drug in randomized controlled trials of primary 
hypertension [49], whereas beta-blockers differ in 
their pharmacokinetic and pharmacodynamic prop-
erties which influence their therapeutic impact on 
patient profiles, and has been discussed elsewhere. 
The main CV use of beta-blockers is to antagonize 
cardiac beta1-adrenoceptor responses in the heart 
and kidneys, whereas some beta-blocking agents 
possess an affinity for specific beta2, alpha1 or beta3 
receptors. The efficacy of beta-blockers depends on 
their mechanisms of action including the degree of 
their lipophilicity, hydrophilicity, drug metabolism 
related to gene polymorphism, intrinsic agonist ac-
tivity, penetration through the blood–brain barrier, 
bioavailability, plasma half-life and vasodilation. 
Smoking status and alterations in central BP have 
also contributed to the negative impact of beta- 
-blockers on outcomes in managing hyperten-
sion. Another meta-analysis reported no major 
differences in BP lowering between atenolol and 
other antihypertensive drug class, however, there 
was a significantly higher mortality, CV mortality 
and risk of stroke with atenolol treatment than 
with other active treatments [50, 51]. Further 
meta-analysis demonstrated the benefits of beta-
-blocker use in reducing CV endpoints in younger 
hypertensive subjects, but not in older patients 
suggesting that age or non-atenolol beta-blocker 
might be an important determinant of outcomes 
in response to beta-blockers in hypertension [52]. 
Most meta-analyses compared the effectiveness of 
beta-blockers on patient prognosis in hypertension 
with the use of atenolol, metoprolol, propranolol, 
and oxprenolol. Despite these findings, clinical 
trials comparing head-to-head outcomes between 
various beta-blockers (including beta-blockers with 
vasodilating effects) in the treatment of hyperten-
sion are lacking. Moreover, previous studies on 
beta-blockers have been primarily designed to 
treat elevated BP, but not to focus on hypertension-
related tachycardia outcomes. 
The use of cardio selective beta-blockers is 
associated with a lower risk of side effects includ-
ing metabolic disorders [53], while binding beta2 
receptors located in lungs, liver, vascular smooth 
muscle or skeletal muscle result in bronchospasm, 
peripheral vasoconstriction, alteration of glucose 
and lipid metabolism [54, 55]. Therapy with a 
cardioselective nebivolol (causing NO-derived 
vasodilation) and non-cardioselective carvedilol 
(causing inhibition of sympathetic alpha-receptors) 
is associated with less side effects and favorable 
metabolic profile in addition to pleiotropic action, 
anti-inflammatory, anticoagulation and antipro-
liferation properties. Nebivolol also positively 
affects adipose tissue via acting as an agonist for 
beta3 adrenoreceptors. Nevertheless, given the 
different mechanisms of action, the magnitude of 
HR reduction with either nebivolol or carvedilol 
will not only take longer in duration but is lower 
compared to cardio-selective beta-blockers without 
intrinsic sympathomimetic activity (i.e. atenolol, 
metoprolol, bisoprolol or betaxolol). Furthermore, 
increasing doses of metoprolol or bisoprolol caused 
further decreases in HR (as expected with beta- 
-blockers), whereas increasing doses of carvedilol 
produced increases in HR, likely as the result of 
a reflex increase in sympathetic activity secondary 
to peripheral vasodilation caused by alpha-blocking 
effects of the drug. In fact, 200 mg of metoprolol 
and 10 mg of bisoprolol are significantly more ef-
fective in reducing HR than 100 mg of carvedilol 
[56, 57]. However, both metoprolol and bisoprolol 
have been shown to induce up-regulation of beta-
adrenoceptor density and to decrease nocturnal 
melatonin release [58–60].
Amongst beta-blockers, betaxolol is a long act-
ing highly selective beta1-blocking agent (half-life 
~19 h) and has several advantages that are likely 
to overcome certain limitations of other beta-
-blockers [61]. Betaxolol provides steady plasma 
concentration, less fluctuation and intersubject, and 
intrasubject variability producing a more consistent 
therapeutic response and more dependable dosage 
adjustment when compared to atenolol [62]. A fur-
ther major advantage of betaxolol is the penetration 
through the blood–brain barrier and the ability to 
antagonize beta1 receptor that are expressed in 
several regions and tracts in the central nervous 
system [61] including the locus coeruleus (LC) 
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and its projections. Notably, the LC is the major 
noradrenergic brain nuclei and the largest source 
of NA production. In this context, it is likely that 
betaxolol may influence the central nervous sys-
tem. In fact, betaxolol administration resulted in a 
rapid reduction of panic anxiety and panic disorder 
attacks, even in patients with longstanding anxiety, 
obsessive-compulsive personality disorder and 
post-traumatic stress [61]. 
Effects of beta-blockers on sympathetic 
activation in hypertension
The contribution of increased sympathetic ac-
tivation to the pathophysiology of hypertension is 
well established. The question therefore arises, how 
lowering the HR and BP will affect MSNA levels. 
Previous studies determining the effects of beta-
-blockers on sympathetic activity in essential hy-
pertension have shown conflicting results. Atenolol 
therapy had no effects on plasma NA levels or total 
body NA spillover in essential hypertension [63]. 
Microneurography studies have also demonstrated 
inconsistent results with an increase in MSNA 
following a short-term therapy with metoprolol in 
patients with untreated essential hypertension [64] 
or increase in MSNA after acute administration of 
atenolol in healthy subjects [65]. Other studies re-
ported no changes in MSNA in response to chronic 
therapy with metoprolol [66] and atenolol [67].
On the contrary, a recent study found age-re-
lated differences in hemodynamic and sympathetic 
profile in hypertension-related tachycardia and age-
dependent autonomic neural responses to betaxolol 
therapy [68]. An 8-week therapy with betaxolol 
resulted in HR and systolic BP decreases in all 
males with untreated essential hypertension and 
ambulatory tachycardia. However, the magnitude 
of HR reduction was greater in younger (–29 ± 4 
bpm, p < 0.001) than older subjects (–17 ± 4 bpm, 
p = 0.002), whereas the degree of BP reduction 
was greater in older subjects (–27 ± 7 mmHg, p 
= 0.007) compared to younger (–13 ± 4 mmHg, p 
= 0.01) males. In older subjects, despite BP and 
HR decreases, there was a significant decrease in 
MSNA (–13 ± 5 bursts/min, p < 0.05). No signifi-
cant changes in MSNA (3 ± 3 bursts/min, p = 0.47) 
were found in younger males at 8 week follow-
up. These findings suggest that betaxolol exerts 
favorable effects on autonomic neural control in 
hypertension-induced tachycardia irrespective of 
age. In this context, further longer-term clinical 
trials on betaxolol are required to determine CV 
outcomes in hypertension-related tachycardia. 
Aside from effective HR, BP and MSNA con-
trol in hypertension-related tachycardia, therapy 
with betaxolol has been found favorable in reduc-
ing maternal BP without any deleterious effect 
on the fetus and the newborn [69]. Furthermore, 
recently a large case-control study in Taiwan found 
that patients with chronic obstructive pulmonary 
disease (COPD) taking selective beta-blockers had 
a lower risk of severe exacerbations compared to 
patients with COPD who experienced a higher risk 
of severe exacerbations during an increased mean 
daily dose of non-cardioselective beta-blockers 
[70]. Amongst selective beta-blockers which COPD 
patients were taking (i.e. acebutolol, atenolol, 
bisoprolol, betaxolol, metoprolol), in particular one 
selective beta-blocker betaxolol had a significantly 
lower risk of severe exacerbations. This study in-
dicates that betaxolol may be the preferred choice 
of selective beta-blocker for patients with COPD, 
whereas non-cardioselective beta-blockers should 
not be prescribed for patients with COPD. 
Non-pharmacological treatment  
of tachycardia
Considering the contribution of elevated HR 
to the development of arterial hypertension and 
patient prognosis, interventions aiming at life-
style changes including physical exercise, weight 
loss, smoking cessation and stress reduction are 
considered effective in lowering fast HR (Fig. 1). 
Despite mounting evidence linking physical 
inactivity to the growing and significant burden of 
chronic disease including CVD, this risk factor con-
tinues to be often ignored in prevention programs. 
Regular physical exercise results in reducing HR, 
increasing parasympathetic activity and decreas-
ing sympathetic activity in the human heart at rest 
[71–74]. While these study protocols were different 
regarding the type of physical activity, duration of 
exercise and follow-up period, it was found that 
regular endurance training led to a decrease of 
resting HR and favorable modulation of autonomic 
neural control, which in turn may contribute to 
improved patient prognosis and reduced mortal-
ity. The HERITAGE Family Study found a small 
but statistically significant decrease of resting HR 
(from a minimum of 2.7 to a maximum of 4.6 bpm) 
in all healthy participants (n = 507) assigned to 
three age-related groups (17–29 years, 30–49 years 
and 50–65 years) following a 20-week endurance 
exercise program [72]. Aerobic physical training 
has been shown to improve cardiac autonomic 
modulation in hypertension independently of an-
6 www.cardiologyjournal.org
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giotensin converting enzyme inhibitor treatment 
[75] and reduce CV mortality risk in cohort studies 
including hypertensive patients [76, 77]. Notably, 
hypertensive subjects benefit from regular physical 
exercise in lowering BP and improve CV outcomes 
[7]. While the magnitude of BP reduction with 
endurance training is greater than other types of 
exercise, more research is needed to determine the 
right dose of exercise [78, 79] and impact of physi-
cal activity on HR levels and associated outcomes 
in hypertension-induced tachycardia.
Given the link between obesity and higher 
resting BP and HR values and resultant autonomic 
impairment characterized by reduced parasym-
pathetic activity and relative predominance of 
sympathetic activity [80], body weight reduction 
is considered as a crucial non-pharmacological ap-
proach in the treatment of tachycardia, metabolic 
abnormalities and elevated BP. In this context, 
clinically important are findings of the very recent 
PREVIEW lifestyle intervention study which 
followed-up 2,500,000 patients with obesity and 
pre-diabetes who underwent a low-energy diet 
for 8 weeks [81]. In this study men and women 
responded differently in terms of HR reduction 
(–6.4 ± 1.1 in men vs. 4.9 ± 1.1 bpm in women). 
In addition to rapid weight loss, an 8-week low 
energy diet was associated with improvements 
in numerous parameters including insulin resist-
ance, metabolic syndrome Z-score, C-peptide, fat 
mass, high density lipoprotein cholesterol, fat-free 
mass, hip circumference and pulse pressure [81]. 
Further proof for HR reduction following weight 
loss 2 years after gastric bypass surgery comes 
from the Utah Obesity Study [82]. In this study, in 
severely obese patients weight loss of an average 
of 100 ± 37 lb was accompanied by a reduction in 
resting HR by –13 bpm and improved HR recovery 
after exercise when compared to the non-surgical 
group (weight loss of 3 ± 22 lb and HR reduction 
by –6 bpm). Whether, and to what extent lowering 
of HR may contribute to reduced CV mortality 
merits further investigation. 
Further proof for reducing HR following weight 
loss has been demonstrated in young normotensive 
males who were randomized to a low-calorie diet, 
therapy with moxonidine, combination of both 
therapies and the control group [83]. Following 
6-month follow-up, weight loss of 7.6 ± 1.9 led to 
a reduction of HR by –11.7 ± 2.7 bpm and MSNA 
by –10.5 ± 2.3 bursts/min which was comparable to 
the effects of a combination of both low-calorie diet 
and moxonidine. Moxonidine alone decreased HR 
by –4.7 ± 3.0 bmp and MSNA by –11.0 ± 1.2 with-
out an impact on body weight [83]. These findings 
suggest that weight loss programs are essential in 
overweight subjects with the potential to reverse 
sympathetic CV profile prior to development of 
established hypertension. 
Amongst lifestyle habits, hypertensive pa-
tients should be counselled to stop smoking. Both 
acute and chronic smoking has been directly linked 
to increases in BP, HR and MSNA levels [84, 85] 
which may play a critical mechanistic role in the 
development and progression of hypertension, 
CVD and mortality. Available evidence indicates 
that smoking cessation almost completely reverses 
risk of CVD, thereby is considered the single most 
effective lifestyle intervention. Quitting smoking 
results in a rapid and persistent drop of HR [86], 
improvement of HR variability [87] and exerts 
beneficial effects on CV health by reducing the 
increased excess risk among former smokers [88].
Stress is another major factor contributing 
to fast HR, development of hypertension, CVD 
and arrhythmias as previously reviewed in detail 
[89]. Non-pharmacological approaches such as 
transcendental meditation, yoga technique and 
slow breathing therapy have been shown to alter 
stress response, modulate cardiac autonomic regu-
lation, increase HR variability and vagal dominance 
[90–94].
Conclusion and clinical perspectives
Prevention of excess CV events and mortal-
ity caused by elevated HR remains a challenging 
problem. While elevated HR can be triggered by 
numerous factors, an appropriate assessment of 
resting HR followed by lifestyle interventions is 
essential in clinical practice in both patient risk 
stratification and prevention of tachycardia-related 
disease. Nearly 1 in 3 hypertensive patients com-
monly demonstrates hyperkinetic hypertension 
at the early course of the disease and tachycardia 
can be an indicator of established hypertension 
associated with obesity, metabolic abnormalities 
and obstructive sleep apnea. Undoubtedly, lifestyle 
modification is the cornerstone for the prevention 
of hypertension, in particular regular physical ac-
tivity, weight loss and smoking cessation should 
be an integral part of treating resting tachycardia 
in uncomplicated hypertension. While studies on 
beta-blockers in the treatment of hypertension 
are inconclusive, notably a therapy with highly 
cardio-selective beta-blocker such as betaxolol can 
effectively reduce HR, BP and modulate sympa-
thetic neural control in patients with tachycardia 
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which is a strong independent risk factor for CV 
events and associated mortality. Given the lack of 
studies comparing head-to-head CV outcomes with 
the use of highly cardio selective beta-blockers 
(i.e. betaxolol, bisoprolol and nebivolol), there is 
an unmet need in continuing clinical trials in hy-
pertension in order to determine the optimal HR 
levels that would preclude tachycardia-mediated 
organ damage. 
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